Share Email Print

Proceedings Paper

Photodynamic therapy in interplay with fluorescence diagnostics in the treatment of human superficial malignancies
Author(s): Torsten Andersson; Roger Berg; Jonas Johansson; Dick Killander; Katarina Svanberg; Sune Svanberg; Yuanlong Yang
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

In the present paper we address the question if fluorescence diagnostics can be used to monitor and possibly predict the outcome of photodynamic therapy (PDT) using the tumor seeking agents Photofrin and (delta) -aminolevulinic acid (ALA). The degree of selective uptake may vary from patient to patient and it would be interesting to use the drug-related fluorescence signal as a tool to tailor the treatment strategy. Clearly, the fluorescence intensity cannot be directly related to the tissue drug contents because of varying absorption and scattering properties of the tissue. However, because of the real-time capability of fluorescence it is interesting to see how far the fluorescence information can be utilized for optimizing the light delivery. Patients with basal cell carcinoma and spread metastatic breast cancer in the skin were treated. Two different doses, 1 and 2 mg/kg b.w. of Photofrin (Quadra Logic, Vancouver, Canada) were used. The treatment laser was a Nd:YAG pumped dye laser (Multilase Dye 600, Technomed International, Paris/Bron, France). The system provides 1064 nm IR and 532 nm green light from the Nd:YAG laser as well as red light in the region 620 - 670 nm from a dye laser. The treatment procedure was preceded by fluorescence measurements for allowing comparisons between the diagnostic signals and the treatment outcome. At the end of the treatment, fluorescence was again monitored to assess the degree of bleaching manifested by the appearance of an additional red peak. Our data on the connection between fluorescence signals, delivered dose and observed treatment outcome are presented and the potential of imaging fluorescence monitoring in PDT dosimetry is discussed.

Paper Details

Date Published: 1 June 1992
PDF: 13 pages
Proc. SPIE 1645, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy, (1 June 1992); doi: 10.1117/12.60941
Show Author Affiliations
Torsten Andersson, Lund Univ. Hospital (Sweden)
Roger Berg, Lund Institute of Technology (Sweden)
Jonas Johansson, Lund Institute of Technology (Sweden)
Dick Killander, Lund Univ. Hospital (Sweden)
Katarina Svanberg, Lund Univ. Hospital (Sweden)
Sune Svanberg, Lund Institute of Technology (Sweden)
Yuanlong Yang, Lund Institute of Technology (United States)

Published in SPIE Proceedings Vol. 1645:
Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy
Thomas J. Dougherty, Editor(s)

© SPIE. Terms of Use
Back to Top